PDE10A

Noema Pharma Appoints Michael Gutch as Chief Financial Officer

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapy, Sofinnova, Board, Growth, Trigeminal neuralgia, Pain, State university system, NASDAQ, Â, Company, TSC, HIG, Safety, Noema, Glutamate (neurotransmitter), Polaris Partners, Corporate development, Tourette syndrome, Tuberous sclerosis complex tumor suppressors, Leadership, H.I.G. Capital, MBA, Patient, Eli Lilly and Company, PDE10A, Seizure, CNS, AstraZeneca, Pharmaceutical industry, Management, Entasis, Indiana University

BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer.

Key Points: 
  • BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer.
  • With his impressive background in healthcare and in senior transactional and operating roles, we look forward to the benefit of his leadership and wealth of experience," said Luigi Costa, Noema Pharma's Chief Executive Officer.
  • "Noema Pharma is making fantastic progress with the development of its clinical pipeline to bring its potentially transformative assets to patients with debilitating CNS conditions," said Michael Gutch, Noema Pharma's Chief Financial Officer.
  • Michael Gutch, Ph.D., joins Noema Pharma from Entasis Therapeutics, where he served as Chief Business Officer and Chief Financial Officer from 2017.

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Therapy, University of California, San Diego Performance-Based Skills Assessment, Nerve injury, Sofinnova, Pain management, Chronic pain, Partnership, Trigeminal nerve, Trigeminal neuralgia, Pain, Sensation, University, Company, TSC, Associate, Safety, Glutamate (neurotransmitter), Polaris Partners, Adult, Neuropathic pain, Tourette syndrome, Tuberous sclerosis complex tumor suppressors, Brain, Patient, PDE10A, Neurology, Solution, Face, Seizure, Pharmaceutical industry

BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN).

Key Points: 
  • BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN).
  • LibraTN is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of NOE-101 in adults with pain associated with TN.
  • "It's very exciting to have dosed our first patient in this Phase 2b trial in trigeminal neuralgia.
  • Lead product NOE-101, an mGluR5 inhibitor, is currently evaluated in pain associated with Trigeminal Neuralgia (TN) and in seizures in Tuberous Sclerosis Complex (TSC).

Noema Pharma Announces FDA Investigational New Drug Authorization for Phase 2b LibraTN Study of mGluR5 Inhibitor NOE-101 in Trigeminal Neuralgia

Retrieved on: 
Monday, February 14, 2022
Trigeminal neuralgia, Morphine, Patient, CNS, Glutamate (neurotransmitter), Food, Trigeminal nerve, Tuberous sclerosis complex tumor suppressors, PDE10A, The Fear Is Excruciating, but Therein Lies the Answer, Brain, Neuropathic pain, IND, Adult, Safety, Seizure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pain, Nerve injury, Investigational New Drug, FDA, Tourette syndrome, Sofinnova, Anticonvulsant, Sensation, Face, GLOBE, TSC, Chronic pain, Pharmaceutical industry

The LibraTN trial is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of NOE-101 in adults with pain associated with TN.

Key Points: 
  • The LibraTN trial is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of NOE-101 in adults with pain associated with TN.
  • The LibraTN study will help us gain further understanding of the efficacy of NOE-101 in patients with TN-associated pain."
  • Noema Pharma is a Swiss-based company targeting orphan CNS diseases characterized by an imbalanced neuronal network.
  • Noema Pharma was seeded by the leading European venture capital firm Sofinnova Partners.

Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering

Retrieved on: 
Wednesday, December 8, 2021
Company, The Washington Campus Board of Directors, American College of Psychiatrists, GLOBE, Tuberous sclerosis complex tumor suppressors, Therapy, Tourette syndrome, Sofinnova, Medical education, University of California, Irvine, Safety, Neuroscience, American Psychiatric Association, Time in Europe, National Stuttering Association, PDE10A, Polaris Partners, Faculty, Patient, Silence, Glutamate (neurotransmitter), American College, Social, Board, Stuttering, Distinguished Fellow of the British Computer Society, CNS, Noema, TSC, University, Trigeminal neuralgia, KOL, Science, Seizure, Saint Louis University School of Medicine, UC, Pharmaceutical industry

Noema's leadership will discuss Noemas PDE10A inhibitor NOE-105 for the management of Childhood Onset Fluency Disorder (stuttering or stammer).

Key Points: 
  • Noema's leadership will discuss Noemas PDE10A inhibitor NOE-105 for the management of Childhood Onset Fluency Disorder (stuttering or stammer).
  • In addition to its commitment to developing treatments for orphan diseases of the CNS, Noema Pharma is leading a therapeutics development intiative with a focus on conditions with no available therapeutic interventions.
  • He serves on the Board of Directors of the World Stuttering Network and is a past Chair of the National Stuttering Association and Vice Chair of the International Stuttering Research.
  • Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks.

Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

Retrieved on: 
Tuesday, November 9, 2021
Seizure, Safety, University, Tourette syndrome, Industry, Therapy, TSC, Tuberous sclerosis complex tumor suppressors, Director, MD, Clinical trial, CEO, Knowledge, MBA, CMR Surgical, Sofinnova, CNS, Board, Chair, PDE10A, Brown University, Company, GLOBE, Solution, Axovant Sciences, Kriyā, Board of directors, Nervous system, Ironwood Pharmaceuticals, Glutamate (neurotransmitter), Central nervous system, Trigeminal neuralgia, Patient, Yale University, Brain, Pharmaceutical industry, Management

"I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma.

Key Points: 
  • "I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma.
  • The two new appointments further expand the Company's board and follow the recent appointment of Jeffrey Jonas MD as the Chairman of the Board of Directors.
  • "I am delighted to be joining Noema Pharma's board and I'm looking forward to working with Noemas dedicated and talented executive team," said Ilise Lombardo MD, Board Member of Noema Pharma.
  • Catherine Moukheibir currently serves on the Board of Directors at DNA Script, Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals and Orphazyme.

Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Retrieved on: 
Monday, October 4, 2021
CNS, Therapy, Clinical trial, Harvard Medical School, PDE10A, National Science and Technology Forum, Science, Patient, Neuropsychiatry, Disability, Board, Senior, Company, TSC, Tuberous sclerosis complex tumor suppressors, Shire (pharmaceutical company), Glutamate (neurotransmitter), Sage, Forest Laboratories, Noema, Leadership, Research and development, Sofinnova, Trigeminal neuralgia, Amherst College, CHF, Safety, Regenerative medicine, Conservative Science & Technology Forum, Polaris Partners, Alembic Pharmaceuticals, Seizure, GLOBE, Director, Pharmaceutical industry

BASEL, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors.

Key Points: 
  • BASEL, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors.
  • "I am delighted that Jeff accepted to join Noema as Chairman of the Board and am looking forward to us working together.
  • Noema will benefit greatly from Jeff's rich experience in the field of neuropsychiatric conditions and his leadership in the biotech industry, said Luigi Costa, Chief Executive Officer of Noema Pharma.
  • "I am very excited to be joining the Noema team with its first clinical trial underway and with more imminent starts, said Jeffrey Jonas, Chairman of the Board of Directors of Noema Pharma.

Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021

Retrieved on: 
Thursday, September 2, 2021
Trigeminal neuralgia, Company, Polaris Partners, Tuberous sclerosis complex tumor suppressors, CNS, GLOBE, Sofinnova, Seizure, TSC, PDE10A, Safety, Tourette syndrome, Glutamate (neurotransmitter), Pharmaceutical industry

BASEL, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two upcoming investor events:

Key Points: 
  • BASEL, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two upcoming investor events:
    Swiss Biotech Day , in-person in Basel, September 6, 2021
    The UBS Biotech Private Company Symposium, virtual, September 22-23, 2021
    Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks.
  • The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages.
  • The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor.
  • Noema Pharma was founded with the leading venture capital firm Sofinnova Partners.

Schizophrenia Drug Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Pharmaceutical, Health, Mental Health, TAAR1, M1, Teva Pharmaceuticals, CYP2D6, United States, Brain, Dnata Singapore, Route, Boehringer Ingelheim, Administration, Therapy, Route of administration, Patient, US Foods, Merck Sharp & Dohme Federal Credit Union, Agonist, Government budget balance, Biotinidase, M4, N-Methyl-D-aspartic acid, Hallucination, Intention, Cognition, Food and Drug Administration, Alzheimer's disease, 5-HT2A receptor, Deuterium, Agitation, Delusion, PDE10A, NDA, Breakthrough therapy, Psychosis, Food, Movement disorders, Risperidone, Pharmaceutical industry, Medical device

The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Schizophrenia - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Schizophrenia pipeline landscape.
  • The companies which have their Schizophrenia drug candidates in the most advanced stage, i.e.
  • Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

Retrieved on: 
Thursday, August 5, 2021
Royal Melbourne Hospital, Clinical trial, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, Sorbonne University, Hospital, Brain, Insulin resistance, Seizure, Patient, Male, CNS, Glutamate (neurotransmitter), Tic, Neuron, PET, Sofinnova, TSC, Adult, Institute, PDE10A, Safety, Neurodevelopmental disorder, Blinking, GLOBE, Pharmaceutical industry

BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.

Key Points: 
  • BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.
  • This dose ranging study will help generate useful data to understand the efficacy and safety of NOE-105 in patients with Tourette Syndrome, said Dr George Garibaldi, Chief Medical Officer of Noema Pharma.
  • Dr Andreas Hartmann said: Tourette Syndrome can be a devastating disease, significantly affecting patients confidence and ability to go about everyday tasks.
  • NOE-105, a PDE10A inhibitor, is in Phase 2 for the treatment of Tourette Syndrome.